Article Information
History
- March 29, 2021.
Article Versions
- Version 1 (March 28, 2021 - 20:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Nicholas A Kennedy, PhD1,2,*,
- Simeng Lin, MBChB1,2,*,
- James R Goodhand, MBBS1,2,*,
- Neil Chanchlani, MBChB1,2,
- Ben Hamilton, MBBS1,2,
- Claire Bewshea, MSc2,
- Rachel Nice, MSc2,3,
- Desmond Chee, MBBS1,2,
- JR Fraser Cummings, DPhil4,
- Aileen Fraser, MSc5,
- Peter M Irving, MD6,7,
- Nikolaos Kamperidis, MD8,
- Klaartje B Kok, PhD9,10,
- Christopher A Lamb, PhD11,12,
- Jonathan Macdonald, BM13,14,
- Shameer J Mehta, MD15,
- Richard CG Pollok, PhD16,17,
- Tim Raine, PhD18,
- Philip J Smith, MBBS19,
- Ajay M Verma, MD20,
- Timothy J McDonald, PhD2,3,
- Shaji Sebastian, MD21,22,
- Charlie W Lees, PhD23,24,
- Nick Powell, PhD25,26,*,
- Tariq Ahmad, DPhil1,2,*,†,
- Contributors to the CLARITY IBD study
- 1Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
- 2Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, UK
- 3Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
- 4Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 5Department of Gastroenterology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
- 6Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
- 7School of Immunology & Microbial Sciences, King’s College London, London, UK
- 8Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK
- 9Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
- 10Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK
- 11Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 12Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
- 13Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
- 14School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK
- 15Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK
- 16Department of Gastroenterology, St George’s University Hospital NHS Foundation Trust, London, UK
- 17Institute for Infection & Immunity, St George’s, University of London, London, UK
- 18Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- 19Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- 20Department of Gastroenterology, Kettering General Hospital, Kettering, UK
- 21IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK
- 22Hull York Medical School, University of Hull, Hull, UK
- 23Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK
- 24Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Gastroenterology, Western General Hospital, Edinburgh, UK
- 25Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK
- 26Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
- ↵†Address for correspondence:
Prof Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK, tariq.ahmad1{at}nhs.net
↵* denotes equal contribution
Posted March 29, 2021.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines
